JW (Cayman) Therapeutics Co. Company Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer.
Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
The company’s pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma.
JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 281 |
| CEO | Min Liu |
Contact Details
Address: Building B Shanghai China | |
| Website | jwtherapeutics.com |
Stock Details
| Ticker Symbol | JWCTF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG5210T1040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Min Liu | Chief Executive Officer and Executive Chairman |
| Dr. Yiping Li M.D. | Co-Founder and Director |